PMID: 11309436Apr 20, 2001Paper

Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial

Journal of the National Cancer Institute
J L AuInternational Mitomycin C Consortium

Abstract

Intravesical chemotherapy (i.e., placement of the drug directly in the bladder) with mitomycin C is beneficial for patients with superficial bladder cancer who are at high risk of recurrence, but standard therapy is empirically based and patient response rates have been variable, in part because of inadequate drug delivery. We carried out a prospective, two-arm, randomized, multi-institutional phase III trial to test whether enhancing the drug's concentration in urine would improve its efficacy. Patients with histologically proven transitional cell carcinoma and at high risk for recurrence were eligible for the trial. Patients in the optimized-treatment arm (n = 119) received a 40-mg dose of mitomycin C, pharmacokinetic manipulations to increase drug concentration by decreasing urine volume, and urine alkalinization to stabilize the drug. Patients in the standard-treatment arm (n = 111) received a 20-mg dose without pharmacokinetic manipulations or urine alkalinization. Both treatments were given weekly for 6 weeks. Primary endpoints were recurrence and time to recurrence. Treatment outcome was examined by use of Kaplan-Meier analysis with log-rank tests. Statistical tests were two-sided. Patients in the two arms did not differ...Continue Reading

Associated Clinical Trials

Mar 1, 2016·John E. Humphrey

References

Sep 1, 1992·Biochemistry·D SiegelD Ross
May 28, 1992·International Journal of Cancer. Journal International Du Cancer·E A De BruijnR A Maes
Jan 1, 1996·Cancer Chemotherapy and Pharmacology·M G WientjesJ L Au
Mar 15, 1996·International Journal of Cancer. Journal International Du Cancer·S V SinghH A Zaren
Oct 29, 1998·General Pharmacology·V J SpanswickJ F Smyth

❮ Previous
Next ❯

Citations

Dec 14, 2004·Der Urologe. Ausg. A·S LangbeinP Alken
Nov 12, 2010·Cancer Chemotherapy and Pharmacology·Antonia TsallasHelen Burt
Nov 30, 2010·World Journal of Urology·Alon Z WeizerJeffrey S Montgomery
Mar 29, 2008·Pharmaceutical Research·Zancong ShenJessie L-S Au
Jan 22, 2013·Current Urology Reports·Yuval FreifeldAvi Stein
Jan 5, 2002·Journal of Controlled Release : Official Journal of the Controlled Release Society·Jessie L-S AuM Guill Wientjes
Aug 6, 2003·Critical Reviews in Oncology/hematology·Per-Uno Malmström
Aug 8, 2006·Molecular Pharmaceutics·Pradeep TyagiLeaf Huang
May 8, 2007·Nature Clinical Practice. Urology·Guido Dalbagni
Dec 21, 2012·Journal of Endourology·Matthew J MauriceRobert Abouassaly
Oct 18, 2001·Journal of the National Cancer Institute·J R Masters
Apr 20, 2001·Journal of the National Cancer Institute·J E Montie
Jul 14, 2010·The AAPS Journal·Leijun HuJessie L-S Au
Jul 12, 2012·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·Gang ChenPeng Jing
Nov 11, 2010·Future Oncology·Ze LuJessie L-S Au
Aug 5, 2011·Indian Journal of Urology : IJU : Journal of the Urological Society of India·M Manoharan
Jul 20, 2010·Immunotherapy·Shahrokh F ShariatGuido Dalbagni
May 13, 2008·European Urology·Marko BabjukUNKNOWN European Association of Urology (EAU)
Sep 23, 2014·Current Urology Reports·Matthew J PaganoJames M McKiernan
Oct 17, 2014·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Teng LiMin Chen
Feb 5, 2014·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·Brant A InmanZeljko Vujaskovic
Apr 13, 2007·Expert Review of Anticancer Therapy·David JosephsonJohn P Stein
Oct 4, 2012·Expert Review of Anticancer Therapy·Willem Oosterlinck, Karel Decaestecker
Aug 13, 2009·Expert Review of Anticancer Therapy·Karl-Dietrich Sievert, Stephan Kruck
Dec 13, 2005·Expert Review of Anticancer Therapy·Hideaki MiyakeMartin E Gleave
Aug 24, 2006·Expert Review of Anticancer Therapy·Christian BolenzMaurice Stephan Michel
Mar 17, 2015·Expert Opinion on Pharmacotherapy·Sanjay G PatelGary D Steinberg
Dec 23, 2011·Expert Opinion on Investigational Drugs·Vladimir Yutkin, Joseph Chin
Mar 9, 2010·Expert Opinion on Pharmacotherapy·Steve K WilliamsMark Soloway
Jun 23, 2009·Expert Opinion on Drug Delivery·M WirthF Gabor
Jan 19, 2010·Expert Opinion on Investigational Drugs·Marc C SmaldoneJeffrey R Gingrich
Oct 20, 2015·Expert Opinion on Drug Delivery·Pradeep TyagiNaoki Yoshimura
May 7, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·Michael J CimaRobert S Langer
Jul 5, 2016·Bladder Cancer·Nicholas E Power, Jonathan Izawa
Feb 4, 2014·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·C PfisterUNKNOWN Les membres du CCAFU
Dec 15, 2015·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·G LaillerT Lebret
Jul 6, 2013·European Urology·Marko BabjukUNKNOWN European Association of Urology

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.